Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1120 related articles for article (PubMed ID: 26200271)

  • 1. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
    Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D
    Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.
    Fan X; Wang Y; Song J; Wu H; Yang M; Lu L; Weng X; Liu L; Nie G
    Cancer Biol Ther; 2019; 20(10):1328-1336. PubMed ID: 31311404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
    Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
    Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development.
    Ding Q; Zhang Z; Liu JJ; Jiang N; Zhang J; Ross TM; Chu XJ; Bartkovitz D; Podlaski F; Janson C; Tovar C; Filipovic ZM; Higgins B; Glenn K; Packman K; Vassilev LT; Graves B
    J Med Chem; 2013 Jul; 56(14):5979-83. PubMed ID: 23808545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective targeting p53
    Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
    Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
    Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
    Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer.
    Zanjirband M; Edmondson RJ; Lunec J
    Oncotarget; 2016 Jun; 7(26):40115-40134. PubMed ID: 27223080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
    Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
    Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
    Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
    J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
    Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
    J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells.
    Ciardullo C; Aptullahoglu E; Woodhouse L; Lin WY; Wallis JP; Marr H; Marshall S; Bown N; Willmore E; Lunec J
    Haematologica; 2019 Dec; 104(12):2429-2442. PubMed ID: 31004033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of Novel p53-MDM2 Inhibitor (RG7388)-Conjugated Platinum
    Liu W; Ma Y; He Y; Liu Y; Guo Z; He J; Han X; Hu Y; Li M; Jiang R; Wang S
    J Med Chem; 2024 Jun; 67(11):9645-9661. PubMed ID: 38776419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.
    Ni L; Xu J; Zhao F; Dai X; Tao J; Pan J; Shi A; Shen Z; Su C; Zhang Y
    Eur J Pharmacol; 2021 May; 899():174054. PubMed ID: 33771522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumour activity of the glycoengineered type II anti-CD20 antibody obinutuzumab (GA101) in combination with the MDM2-selective antagonist idasanutlin (RG7388).
    Herting F; Herter S; Friess T; Muth G; Bacac M; Sulcova J; Umana P; Dangl M; Klein C
    Eur J Haematol; 2016 Nov; 97(5):461-470. PubMed ID: 26993060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.
    Phelps D; Bondra K; Seum S; Chronowski C; Leasure J; Kurmasheva RT; Middleton S; Wang D; Mo X; Houghton PJ
    Pediatr Blood Cancer; 2015 Aug; 62(8):1345-52. PubMed ID: 25832557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor Trametinib.
    Berberich A; Kessler T; Thomé CM; Pusch S; Hielscher T; Sahm F; Oezen I; Schmitt LM; Ciprut S; Hucke N; Ruebmann P; Fischer M; Lemke D; Breckwoldt MO; von Deimling A; Bendszus M; Platten M; Wick W
    Clin Cancer Res; 2019 Jan; 25(1):253-265. PubMed ID: 30274984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
    Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
    Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.